US20130089573A1 - Novel process - Google Patents
Novel process Download PDFInfo
- Publication number
- US20130089573A1 US20130089573A1 US13/702,691 US201113702691A US2013089573A1 US 20130089573 A1 US20130089573 A1 US 20130089573A1 US 201113702691 A US201113702691 A US 201113702691A US 2013089573 A1 US2013089573 A1 US 2013089573A1
- Authority
- US
- United States
- Prior art keywords
- oil
- water emulsion
- filter
- filtering
- sterile grade
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
Definitions
- the present invention relates to improved processes for the production of submicron oil in water emulsions, in particular, filtration of submicron oil in water emulsions.
- Oil in water emulsions can be used in vaccine/immunogenic compositions as adjuvants. As these emulsions are administered to humans it is necessary that the emulsions are sterile. Oil in water emulsions used as adjuvants are submicron emulsions and the oil droplets are sufficiently small to be sterile-filtered through 0.2 ⁇ m filtered. It is an object of the present invention to provide a process for the production of submicron oil in water emulsions and in particular filtration of oil in water emulsions.
- the present invention relates to a process for production of submicron oil in water emulsion, in particular, filtration of submicron oil in water emulsions.
- the present invention provides processes for the production of a submicron oil in water emulsion comprising the steps:
- Oil in water emulsions can be used as immunological adjuvants.
- Vaccine composition comprising said oil in water emulsions in combination with an antigen, such as an influenza antigens are administered parenterally and thus it is necessary for the oil in water emulsion to be sterile.
- an antigen such as an influenza antigens
- the present inventors have demonstrated that in order to produce a sterile submicron oil in water emulsion is not sufficient to filter the emulsion through a single sterile grade filter.
- the inventors have shown that in order to provide a sterile oil in water emulsion it is necessary to prefilter the oil in water emulsion prior to filtration with a sterile grade filter.
- the present invention provides a process for the production of a submicron oil in water emulsion comprising the steps:
- the filter used in step c) can have pores with the size ranging those of a sterile grade filter (i.e. about 0.2 ⁇ m), to a pore size of about 2 ⁇ m.
- the pore size of the filter used in step c) in the embodiment above ranges from the size of those of a sterile grade filter sterile grade filter to the size of about 1 ⁇ m.
- the pore size of the filter used in step b) is about 2 ⁇ m, about 2.5 ⁇ m, about 1 ⁇ m, about 0.9 ⁇ m, about 0.8 ⁇ m, about 0.9 ⁇ m, about 0.7 ⁇ m, about 0.6 ⁇ m, about 0.5 ⁇ m, 0.45 ⁇ m or sterile grade for example about 0.2 ⁇ m, for example 0.22 ⁇ m.
- a submicron oil in water emulsion is an oil in water emulsion in which the average droplet size is less than 1 ⁇ m.
- Methods of measuring droplet size are well known to the skilled person e.g. dynamic light scattering.
- Submicron oil in water emulsions can be produced by methods known to the person skilled on the art such as, but not limited to, high pressure homogenisation, for example using a microfluidiser.
- submicron oil in water emulsions have an average oil droplet size of less than about 220 nm (0.2 ⁇ m), in particular between about 120 nm and about 180 nm.
- sterile grade filter it is meant a filter that produces a sterile effluent after being challenged by microorganisms at a challenge level of greater than or equal to 1 ⁇ 10 7 /cm 2 of effective filtration area.
- Sterile grade filters are well known to the person skilled in the art of the invention and have a pore size of about 0.2 ⁇ m, and thus include filters with a pore size of about 0.22 ⁇ m.
- the membranes of the filter can be made from any suitable material known to the skilled person, for example, but not limited to cellulose acetate, polyethersulfone (PES), polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE).
- PES polyethersulfone
- PVDF polyvinylidene fluoride
- PTFE polytetrafluoroethylene
- one or more or all of the filter membranes of the present invention comprise polyethersulfone, for example hydrophilic polyethersulfone.
- the filter used instep b) and/or step d) can have pores with the size ranging from sterile grade filter (about 0.2 ⁇ m) to about 2 ⁇ m, in particular sterile grade filter to about 1 ⁇ m.
- the pore size of the filter used in step b) and/or d) is about 2 ⁇ m, about 2.5 ⁇ m, about 1 ⁇ m, about 0.9 ⁇ m, about 0.8 ⁇ m, about 0.9 ⁇ m, about 0.7 ⁇ m, about 0.6 ⁇ m, about 0.5 ⁇ m, 0.45 ⁇ m or sterile grade for example about 0.2 ⁇ m, for example 0.22 ⁇ m.
- the filter used in steps b) and d) can have the same porosity to each other or have different pore sizes to each other.
- differential pressure of each filter is about 1 to about 1.5 bar, for example about 1 bar.
- processes of the invention wherein filtration is performed at a temperature of between about 15° C. and about 30° C., about 16° C. and about 29° C., about 17° C. and about 28° C., about 16° C. and about 27° C., about 16° C. and about 28° C. or 22° C. ⁇ 4° C.
- the submicron oil in water emulsions comprise between about 2% and about 15%, about 4% and about 12% oil, about 5% and about 10%, about 4% and about 6%, about 8% and about 12%, for example about 5% or 10% (v/v) oil.
- oil in water emulsions of the invention comprises a metabolisable oil, in a particular embodiment oil in water emulsions of the invention comprise squalene (for example between about 4% and 6% [v/v]).
- Oil in water emulsions of the invention may also comprise a tocol.
- Tocols are well known in the art and are described in EP0382271.
- the tocol is ⁇ -tocopherol or a derivative thereof such as alpha-tocopherol succinate (also known as vitamin E succinate).
- an oil in water emulsion of the invention comprising squalene (for example about 5% [v/v]) and ⁇ -tocopherol (for example about 5% [v/v]).
- Oil in water emulsions of the invention comprise one or more surfactants.
- Suitable surfactants are well known to the skilled person and include, but are not limited to polyoxyethylene sorbitan monooleate (TWEEN 80, POLYSORBATE 80), sorbitan triolate (SPAN 85), phosphatidylcholine (lecithin), polyoxyethylene (12) cetostearyl ether and octoxynol-9 (TRITON X-100).
- oil in water emulsions comprise is polyoxyethylene sorbitan monooleate (TWEEN 80, POLYSORBATE 80).
- oil in water emulsions of the invention comprise polyoxyethylene sorbitan monooleate (TWEEN 80) and a further surfactant, in particular sorbitan trioleate (SPAN 85).
- the oil in water emulsion comprises a metabolisable oil (e.g. squalene), a tocol (e.g. ⁇ -tocopherol) and a surfactant (e.g. polyoxyethylene sorbitan monooleate [TWEEN 80, POLYSORBATE 80]).
- a metabolisable oil e.g. squalene
- a tocol e.g. ⁇ -tocopherol
- a surfactant e.g. polyoxyethylene sorbitan monooleate [TWEEN 80, POLYSORBATE 80]
- oil in water emulsions of the invention comprise a metabolisable oil (e.g. squalene), a surfactant (e.g. polyoxyethylene sorbitan monooleate [Polysorbate 80]), and optionally a second surfactant (e.g. sorbitan trioleate [Span 85]).
- a metabolisable oil e.g. squalene
- a surfactant e.g. polyoxyethylene sorbitan monooleate [Polysorbate 80]
- a second surfactant e.g. sorbitan trioleate [Span 85]
- oil in water emulsions of the invention comprise a metabolisable oil (e.g. squalene), a polyoxyethylene alkyl ether hydrophilic non-ionic surfactant (e.g. polyoxyethylene (12) cetostearyl ether) and a hydrophobic non-ionic surfactant (e.g. polyoxyethylene sorbitan monooleate [Polysorbate 80]), or sorbitan trioleate [Span 85]).
- a metabolisable oil e.g. squalene
- a polyoxyethylene alkyl ether hydrophilic non-ionic surfactant e.g. polyoxyethylene (12) cetostearyl ether
- a hydrophobic non-ionic surfactant e.g. polyoxyethylene sorbitan monooleate [Polysorbate 80]
- sorbitan trioleate sorbitan trioleate
- Embodiments herein relating to “vaccine compositions” of the invention are also applicable to embodiments relating to “immunogenic compositions” of the invention, and vice versa.
- Aqueous phase was prepared in tank 2 , by mixing water for injection, phosphate buffer saline and Tween.
- Oil phase was prepared in tank 1 , by mixing tocopherol and squalene. Both phases were stirred until homogeneity was obtained. The whole installation was flushed with nitrogen in order to avoid tocopherol oxidation.
- High pressure homogenizer was fed with a membrane pump. Both phases were fed together, with the required flow rate ratio. Both phases first pass through a high shear homogenizer where a coarse emulsion was obtained. Then, in line with the high shear homogenizer, the product entered the high pressure homogenizer, were the fine emulsion was obtained.
- the product was harvested in tank 3 (first pass).
- tank 2 and 1 were empty, emulsion from tank 3 was directed towards the inlet of the mixing device and a second pass was performed.
- the product is harvested in tank 2 .
- tank 3 was empty, the emulsion from tank 2 was directed towards the inlet of the mixing device and a third pass was performed.
- the emulsion was harvested in tank 3 and stored under nitrogen until filtration.
- Filtration is performed on two sterilizing filters comprising combined 0.5/0.2 ⁇ m membranes, at a maximum pressure of 1 bar, at a temperature ranging between 18 and 26° C., and for a contact time of maximum 3 hours.
- the filter membrane has to be challenged with B. diminuta suspended in the emulsion at a concentration of 10 7 CFU/cm 2 of membrane. Several set-up were tested in order to find the best configuration.
- the product was inoculated with B. diminuta bacteria at a concentration of 10 7 CFU/cm 2 of membrane and filtrated on two 0.5/0.2 ⁇ m filters at a maximum pressure of 1 bar and at a temperature ranging between 18 and 26° C.
- the contact time between the inoculated product and the filter was 3 hours maximum.
- the product was first prefiltrated on a 0.5 ⁇ m flat membrane.
- the product was then inoculated with B. diminuta bacteria at a concentration of 10 7 CFU/cm 2 of membrane and filtrated on a 0.2 or on a 0.5/0.2 or on a 0.2/0.2 ⁇ m flat membrane(s) at a maximum pressure of 1 bar and at a temperature ranging between 18 and 26° C.
- the contact time between the inoculated product and the filter was 1.5 hours maximum.
- the product was first prefiltrated on a capsule containing a 0.5 and a 0.2 ⁇ m filters.
- the product was then inoculated with B. diminuta bacteria at a concentration of 10 7 CFU/cm 2 of membrane and filtrated on a 0.2 ⁇ m capsule at a maximum pressure of 1 bar and at a temperature ranging between 18 and 26° C.
- the contact time between the inoculated product and the filter was 3 hours maximum.
- the filtrates were harvested after the last sterilizing membrane and the whole volumes were filtrated on 0.45 ⁇ m collection filters in order to identify the presence of B. dimunita .
- 0.45 ⁇ m filters were plated on a TSA plate and incubated for 7 days at 30° C. The plate where then visually inspected on day 2, 3, 4 and 7. If colonies were observed they were counted and identified.
Abstract
The present invention provides processes for the production of a submicron oil in water emulsion comprising the steps of preparing a submicron oil in water emulsion; pre-filtering the oil in water emulsion through a first sterile grade filter and again filtering the oil in water emulsion through a second sterile grade filter.
Description
- The present invention relates to improved processes for the production of submicron oil in water emulsions, in particular, filtration of submicron oil in water emulsions.
- Methods of manufacture are disclosed in Ott et al., 2000 (The Adjuvant MF59: A 10-year Perspective. Vaccine Adjuvants: Preparation methods and Research Protocols [Methods in Molecular medicine, Vol. 42, Chapter 12, p211-228], Ott et al., 1995 (MF59—Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines: Vaccine Design, the Subunit and Adjuvant Approach [Pharmaceutical Biotechnology volume 6] eds. Powell & Newman, WO06/100110A1 and Lidgate et al., 1992 (Sterile Filtration of a Parenteral Emulsion. Pharmaceuticals Research 9(7): 860-863).
- Oil in water emulsions can be used in vaccine/immunogenic compositions as adjuvants. As these emulsions are administered to humans it is necessary that the emulsions are sterile. Oil in water emulsions used as adjuvants are submicron emulsions and the oil droplets are sufficiently small to be sterile-filtered through 0.2 μm filtered. It is an object of the present invention to provide a process for the production of submicron oil in water emulsions and in particular filtration of oil in water emulsions.
- The present invention relates to a process for production of submicron oil in water emulsion, in particular, filtration of submicron oil in water emulsions.
- The present invention provides processes for the production of a submicron oil in water emulsion comprising the steps:
-
- a. preparing a submicron oil in water emulsion;
- b. pre-filtering the oil in water emulsion through sterile grade filter.
- c. filtering an oil in water emulsion filtered according to step b) through a sterile grade filter separate to that of step b).
- Oil in water emulsions, particularly submicron oil in water emulsions can be used as immunological adjuvants. Vaccine composition comprising said oil in water emulsions in combination with an antigen, such as an influenza antigens are administered parenterally and thus it is necessary for the oil in water emulsion to be sterile. The present inventors have demonstrated that in order to produce a sterile submicron oil in water emulsion is not sufficient to filter the emulsion through a single sterile grade filter. The inventors have shown that in order to provide a sterile oil in water emulsion it is necessary to prefilter the oil in water emulsion prior to filtration with a sterile grade filter.
- Accordingly, the present invention provides a process for the production of a submicron oil in water emulsion comprising the steps:
-
- a. preparing a submicron oil in water emulsion;
- b. pre-filtering the oil in water emulsion through sterile grade filter.
- c. filtering an oil in water emulsion filtered according to step b) through a sterile grade filter separate to that of step b).
- In a further embodiment of the invention there is provided a process for the production of a submicron oil in water emulsion comprising the steps:
-
- a. preparing a submicron oil in water emulsion;
- b. pre-filtering the oil in water emulsion through sterile grade filter;
- c. filtering an oil in water emulsion pre-filtered according to step b) through a filter separate to that of step b); and
- d. filtering an oil in water emulsion filtered according to step c) through a sterile grade filter separate to that of step b) or c).
- In this particular embodiment, the filter used in step c) can have pores with the size ranging those of a sterile grade filter (i.e. about 0.2 μm), to a pore size of about 2 μm. In particular, the pore size of the filter used in step c) in the embodiment above ranges from the size of those of a sterile grade filter sterile grade filter to the size of about 1 μm. For example, the pore size of the filter used in step b) is about 2 μm, about 2.5 μm, about 1 μm, about 0.9 μm, about 0.8 μm, about 0.9 μm, about 0.7 μm, about 0.6 μm, about 0.5 μm, 0.45 μm or sterile grade for example about 0.2 μm, for example 0.22 μm.
- A submicron oil in water emulsion is an oil in water emulsion in which the average droplet size is less than 1 μm. Methods of measuring droplet size are well known to the skilled person e.g. dynamic light scattering. Submicron oil in water emulsions can be produced by methods known to the person skilled on the art such as, but not limited to, high pressure homogenisation, for example using a microfluidiser. In a particular embodiment of the invention, submicron oil in water emulsions have an average oil droplet size of less than about 220 nm (0.2 μm), in particular between about 120 nm and about 180 nm.
- By “sterile grade filter” it is meant a filter that produces a sterile effluent after being challenged by microorganisms at a challenge level of greater than or equal to 1×107/cm2 of effective filtration area. Sterile grade filters are well known to the person skilled in the art of the invention and have a pore size of about 0.2 μm, and thus include filters with a pore size of about 0.22 μm.
- The membranes of the filter can be made from any suitable material known to the skilled person, for example, but not limited to cellulose acetate, polyethersulfone (PES), polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE). In a particular embodiment of the invention one or more or all of the filter membranes of the present invention comprise polyethersulfone, for example hydrophilic polyethersulfone.
- In a further embodiment of the invention there is provided a process as described herein comprising the steps;
-
- a. preparing a submicron oil in water emulsion;
- b. pre-filtering the oil in water emulsion;
- c. filtering an oil in water emulsion pre-filtered according to step b) through a sterile grade filter;
- d. filtering an oil in water emulsion filtered according to step c) through a filter separate to that of step b) or step c);
- e. filtering an oil in water emulsion filtered according to step d) through a sterile grade filter separate to that of step b), c) and/or d).
- In this particular embodiment, the filter used instep b) and/or step d) can have pores with the size ranging from sterile grade filter (about 0.2 μm) to about 2 μm, in particular sterile grade filter to about 1 μm. For example, the pore size of the filter used in step b) and/or d) is about 2 μm, about 2.5 μm, about 1 μm, about 0.9 μm, about 0.8 μm, about 0.9 μm, about 0.7 μm, about 0.6 μm, about 0.5 μm, 0.45 μm or sterile grade for example about 0.2 μm, for example 0.22 μm. The filter used in steps b) and d) can have the same porosity to each other or have different pore sizes to each other.
- In a particular embodiment of the invention, there is provided processes of the invention wherein the differential pressure of each filter is about 1 to about 1.5 bar, for example about 1 bar.
- In a further embodiment, there is provided processes of the invention wherein filtration is performed at a temperature of between about 15° C. and about 30° C., about 16° C. and about 29° C., about 17° C. and about 28° C., about 16° C. and about 27° C., about 16° C. and about 28° C. or 22° C.±4° C.
- In an embodiment of the invention, the submicron oil in water emulsions comprise between about 2% and about 15%, about 4% and about 12% oil, about 5% and about 10%, about 4% and about 6%, about 8% and about 12%, for example about 5% or 10% (v/v) oil.
- In order for any oil in water composition to be suitable for human administration, the oil phase must comprise a metabolisable oil (i.e. biodegradable). The oil may be any vegetable oil, fish oil, animal oil or synthetic oil, which is not toxic to the recipient and is capable of being transformed by metabolism. Nuts, seeds, and grains are common sources of vegetable oils. Synthetic oils are also suitable. Accordingly, oil in water emulsions of the invention comprises a metabolisable oil, in a particular embodiment oil in water emulsions of the invention comprise squalene (for example between about 4% and 6% [v/v]).
- Oil in water emulsions of the invention may also comprise a tocol. Tocols are well known in the art and are described in EP0382271. In particular, the tocol is α-tocopherol or a derivative thereof such as alpha-tocopherol succinate (also known as vitamin E succinate).
- In a particular embodiment of the invention, there is provided an oil in water emulsion of the invention comprising squalene (for example about 5% [v/v]) and α-tocopherol (for example about 5% [v/v]).
- Oil in water emulsions of the invention comprise one or more surfactants. Suitable surfactants are well known to the skilled person and include, but are not limited to polyoxyethylene sorbitan monooleate (TWEEN 80, POLYSORBATE 80), sorbitan triolate (SPAN 85), phosphatidylcholine (lecithin), polyoxyethylene (12) cetostearyl ether and octoxynol-9 (TRITON X-100). In a particular embodiment of the invention oil in water emulsions comprise is polyoxyethylene sorbitan monooleate (TWEEN 80, POLYSORBATE 80). In a further embodiment, oil in water emulsions of the invention comprise polyoxyethylene sorbitan monooleate (TWEEN 80) and a further surfactant, in particular sorbitan trioleate (SPAN 85).
- In a particular embodiment of the invention the oil in water emulsion comprises a metabolisable oil (e.g. squalene), a tocol (e.g. α-tocopherol) and a surfactant (e.g. polyoxyethylene sorbitan monooleate [TWEEN 80, POLYSORBATE 80]).
- In a further embodiment of the invention, oil in water emulsions of the invention comprise a metabolisable oil (e.g. squalene), a surfactant (e.g. polyoxyethylene sorbitan monooleate [Polysorbate 80]), and optionally a second surfactant (e.g. sorbitan trioleate [Span 85]).
- In a further embodiment of the invention, oil in water emulsions of the invention comprise a metabolisable oil (e.g. squalene), a polyoxyethylene alkyl ether hydrophilic non-ionic surfactant (e.g. polyoxyethylene (12) cetostearyl ether) and a hydrophobic non-ionic surfactant (e.g. polyoxyethylene sorbitan monooleate [Polysorbate 80]), or sorbitan trioleate [Span 85]).
- Embodiments herein relating to “vaccine compositions” of the invention are also applicable to embodiments relating to “immunogenic compositions” of the invention, and vice versa.
- The terms “comprising”, “comprise” and “comprises” herein are intended by the inventors to be optionally substitutable with the terms “consisting of”, “consist of” and “consists of”, respectively, in every instance.
- The term “about” in relation to a numerical value×means×±5% or 10%.
- Aqueous phase was prepared in tank 2, by mixing water for injection, phosphate buffer saline and Tween. Oil phase was prepared in tank 1, by mixing tocopherol and squalene. Both phases were stirred until homogeneity was obtained. The whole installation was flushed with nitrogen in order to avoid tocopherol oxidation.
- High pressure homogenizer was fed with a membrane pump. Both phases were fed together, with the required flow rate ratio. Both phases first pass through a high shear homogenizer where a coarse emulsion was obtained. Then, in line with the high shear homogenizer, the product entered the high pressure homogenizer, were the fine emulsion was obtained.
- At the outlet of the mixing device, the product was harvested in tank 3 (first pass). When tank 2 and 1 were empty, emulsion from tank 3 was directed towards the inlet of the mixing device and a second pass was performed. At the end of the second pass, the product is harvested in tank 2. When tank 3 was empty, the emulsion from tank 2 was directed towards the inlet of the mixing device and a third pass was performed. The emulsion was harvested in tank 3 and stored under nitrogen until filtration.
- Filtration is performed on two sterilizing filters comprising combined 0.5/0.2 μm membranes, at a maximum pressure of 1 bar, at a temperature ranging between 18 and 26° C., and for a contact time of maximum 3 hours. In order to demonstrate the efficiency of the filtration process, the filter membrane has to be challenged with B. diminuta suspended in the emulsion at a concentration of 107 CFU/cm2 of membrane. Several set-up were tested in order to find the best configuration.
- In the first set-up, the product was inoculated with B. diminuta bacteria at a concentration of 107 CFU/cm2 of membrane and filtrated on two 0.5/0.2 μm filters at a maximum pressure of 1 bar and at a temperature ranging between 18 and 26° C. The contact time between the inoculated product and the filter was 3 hours maximum.
- Alternatively, the product was first prefiltrated on a 0.5 μm flat membrane. The product was then inoculated with B. diminuta bacteria at a concentration of 107 CFU/cm2 of membrane and filtrated on a 0.2 or on a 0.5/0.2 or on a 0.2/0.2 μm flat membrane(s) at a maximum pressure of 1 bar and at a temperature ranging between 18 and 26° C. The contact time between the inoculated product and the filter was 1.5 hours maximum.
- Finally, the product was first prefiltrated on a capsule containing a 0.5 and a 0.2 μm filters. The product was then inoculated with B. diminuta bacteria at a concentration of 107 CFU/cm2 of membrane and filtrated on a 0.2 μm capsule at a maximum pressure of 1 bar and at a temperature ranging between 18 and 26° C. The contact time between the inoculated product and the filter was 3 hours maximum.
- In all the cases, the filtrates were harvested after the last sterilizing membrane and the whole volumes were filtrated on 0.45 μm collection filters in order to identify the presence of B. dimunita. 0.45 μm filters were plated on a TSA plate and incubated for 7 days at 30° C. The plate where then visually inspected on day 2, 3, 4 and 7. If colonies were observed they were counted and identified.
- With no prefiltration or 0.5 μm prefiltration were applied, volume passed through the filter before clogging were smaller then the minimal retention volume needed to reach the target retention volume of 19.14 ml/cm2 needed to met the BCT requirements of 107CFU/cm2. When pre-filtration with a capsule containing 0.5/0.2 membranes was used as prefilter, then the retention volume increase up to 19.4 ml/cm2 and no passage at all was observed.
-
Retention volume Cond. Prefilter Filter Pressure Set-up (ml/cm2)(1) Passage BCT 1 none (0.5/0.2 1 bar Flat 1.69 0 Fail μm) × 2 menbrane 2 none (0.5/0.2 1 bar Flat 2.35 0 Fail μm) × 2 menbrane 3 0.5 μm 0.5/0.2 1 bar Flat 3.67 0 Fail μm menbrane 4 0.5 μm 0.2 μm 1 bar Flat 12.35 1 Fail menbrane 5 0.5 μm 0.2/0.2 1 bar Flat 0.07 0 Fail μm menbrane 6 0.5/0.2 0.5/0.2 1 bar Capsule >19.14 0 Pass μm μm 7 0.5/0.2 0.5/0.2 1 bar Capsule >19.14 0 Pass μm μm 8 0.5/0.2 0.5/0.2 1 bar Capsule >19.14 0 Pass μm μm (1) in order to meet the BCT conditions (107 CFU/cm2), the retention volume has to be higher than 19.14 ml/cm2. - These results demonstrated that, for emulsions, performing a pre-filtration involving at least a 0.2 μm filter improved the capacity of the sterilizing filter and was a pre-requisite to demonstrate obtaining of a sterile effluent.
Claims (18)
1. A process for the production of a submicron oil in water emulsion comprising the steps:
a. preparing a submicron oil in water emulsion;
b. pre-filtering the oil in water emulsion through sterile grade filter.
c. filtering an oil in water emulsion filtered according to step b) through a sterile grade filter separate to that of step b).
2. The process as claimed in claim 1 comprising the steps:
a. preparing a submicron oil in water emulsion;
b. pre-filtering the oil in water emulsion through sterile grade filter;
c. filtering an oil in water emulsion pre-filtered according to step b) through a filter separate to that of step b); and
d. filtering an oil in water emulsion filtered according to step c) through a filter separate to that of step b) or c).
3. The process according to claim 2 comprising the steps;
a. preparing a submicron oil in water emulsion;
b. pre-filtering the oil in water emulsion;
c. filtering an oil in water emulsion pre-filtered according to step b) through a sterile grade filter;
d. filtering an oil in water emulsion filtered according to step c) through a filter separate to that of step b) or step c);
e. filtering an oil in water emulsion filtered according to step d) through a sterile grade filter separate to that of steps b), c) and/or d).
4. The process of any preceding claim where one or more filter membranes comprise polyethersulfone, for example hydrophilic polyethersulfone.
5. The process of any one of claims 1 to 4 wherein the sterile grade filter has a pore size of about 0.2 μm, for example 0.22 μm.
6. The process according to any one of claim 2 , 4 or 5 wherein the filter used in step c) has a pose size from between sterile grade to about 2 μm for example about 2 μm, about 1.5 μm, about 1 μm, about 0.9 μm, about 0.8 μm, about 0.9 μm, about 0.7 μm, about 0.6 μm, about 0.5 μm, 0.45 μm or sterile grade for example about 0.2 μm, for example 0.22 μm.
7. The process of any one of claims 3 to 5 wherein the filter used in step b) and/or step d) can have pores with the size ranging from sterile grade filter (about 0.2 μm) to about 2 μm, in particular sterile grade filter to about 1 μm, for example, about 2 μm, about 2.5 μm, about 1 μm, about 0.9 μm, about 0.8 μm, about 0.9 μm, about 0.7 μm, about 0.6 μm, about 0.5 μm, 0.45 μm or sterile grade for example about 0.2 μm, for example 0.22 μm.
8. The process of any preceding claim wherein the differential pressure of each filter is about 1 to about 1.5 bar, for example about 1 bar.
9. The process of any preceding claim where in filtration is performed between 15° C. and 30° C., 16° C. and 29° C., 17° C. and 28° C., 16° C. and 27° C., 16 ° C. and 28° C. or about 22° C±4° C.
10. The process according to any preceding claim wherein the oil in water emulsion comprises between 2% and 15% (v/v) oil.
11. The process of claim wherein the submicron oil in water emulsion comprises between 4% and 6% (v/v) oil.
12. The process of any preceding claim wherein the oil in water emulsion comprises between 8 and 12% (v/v) oil.
13. The process according to any preceding claim wherein the submicron oil in water emulsion comprises squalene and one or more surfactants.
14. The process according to any one of claims wherein the submicron oil in water emulsion comprises squalene, a tocol and a surfactant.
15. The process of claim 14 wherein the tocol is α-tocopherol.
16. The process of any one of claims 13 to 15 where in the surfactant is polyoxyethylene sorbitan monooleate (TWEEN 80/POLYSORBATE 80).
17. The process of claim 16 wherein the submicron oil in water emulsion comprises squalene, polyoxyethylene sorbitan monooleate (TWEEN 80) and sorbitan trioleate (SPAN 85).
18. The process according to claim 13 wherein the submicron oil in water emulsion comprises squalene, a polyoxyethylene alkyl ether hydrophilic non-ionic surfactant and a hydrophobic non-ionic surfactant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1009676.6 | 2010-06-10 | ||
GBGB1009676.6A GB201009676D0 (en) | 2010-06-10 | 2010-06-10 | Novel process |
PCT/EP2011/059489 WO2011154444A1 (en) | 2010-06-10 | 2011-06-08 | Novel process |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/059489 A-371-Of-International WO2011154444A1 (en) | 2010-06-10 | 2011-06-08 | Novel process |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/679,198 Division US10406101B2 (en) | 2010-06-10 | 2015-04-06 | Process for the production of a submicron oil in water emulsion |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130089573A1 true US20130089573A1 (en) | 2013-04-11 |
Family
ID=42471407
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/702,691 Abandoned US20130089573A1 (en) | 2010-06-10 | 2011-06-08 | Novel process |
US14/679,198 Active 2031-11-02 US10406101B2 (en) | 2010-06-10 | 2015-04-06 | Process for the production of a submicron oil in water emulsion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/679,198 Active 2031-11-02 US10406101B2 (en) | 2010-06-10 | 2015-04-06 | Process for the production of a submicron oil in water emulsion |
Country Status (8)
Country | Link |
---|---|
US (2) | US20130089573A1 (en) |
EP (1) | EP2579850A1 (en) |
JP (3) | JP2013528196A (en) |
CN (1) | CN102917688B (en) |
BR (1) | BR112012031490A2 (en) |
CA (1) | CA2801984A1 (en) |
GB (1) | GB201009676D0 (en) |
WO (1) | WO2011154444A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130084309A1 (en) * | 2010-06-10 | 2013-04-04 | Glaxosmithkline Biologicals S.A. | Process for the preparation of o/w emulsion |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
JP6324961B2 (en) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | Combination vaccine of serogroup B meningococcus and D / T / P |
EP2906239A1 (en) | 2012-10-12 | 2015-08-19 | GlaxoSmithKline Biologicals SA | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
JP2016502994A (en) | 2012-12-18 | 2016-02-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Conjugates to protect against diphtheria and / or tetanus |
EP4171629A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
AU2021330836A1 (en) | 2020-08-24 | 2023-05-04 | Glaxosmithkline Biologicals Sa | Covid-19 vaccines with tocopherol-containing squalene emulsion adjuvants |
EP4313137A1 (en) | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
BR112023027401A2 (en) | 2021-06-28 | 2024-03-12 | Glaxosmithkline Biologicals Sa | INFLUENZA VIRUS ANTIGENS |
WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023061993A1 (en) | 2021-10-13 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Polypeptides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192222A1 (en) * | 2002-07-23 | 2005-09-01 | Johann Eibl | Pharmaceutical preparations and medicine capable of generating and/or containing thrombin |
US20110162982A1 (en) * | 2009-12-03 | 2011-07-07 | Novartis Vaccines and Diagnostic, GmbH & Co. KG | Methods for producing vaccine adjuvants |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816247A (en) * | 1985-09-11 | 1989-03-28 | American Cyanamid Company | Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs |
DK0382271T3 (en) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoler as adjuvants in vaccines |
EP0656779B1 (en) * | 1992-08-28 | 2000-04-12 | Pharmos Corporation | Submicron emulsions as ocular drug delivery vehicles |
US6645463B1 (en) | 1994-05-16 | 2003-11-11 | The Board Of Regents Of The University Of Michigan | Blood-pool selective carrier for lipophilic imaging agents |
ZA963183B (en) * | 1995-05-16 | 1996-08-26 | Bracco Spa | Process for the depyrogenation of injectable pharmaceutical solutions |
JP2975943B2 (en) | 1996-02-20 | 1999-11-10 | 農林水産省食品総合研究所長 | Emulsion manufacturing method and emulsion manufacturing apparatus |
US6168718B1 (en) | 1996-11-08 | 2001-01-02 | Pall Corporation | Method for purifying blood plasma and apparatus suitable therefor |
GB0416120D0 (en) | 2004-07-19 | 2004-08-18 | Health Prot Agency | Stable compositions containing OMV's |
EP1829958A1 (en) * | 2004-11-30 | 2007-09-05 | Dml Co., Ltd. | Measuring kit for microbe in liquid sample, and relevant measuring method and measuring apparatus |
EP1861120B1 (en) | 2005-03-23 | 2016-05-25 | GlaxoSmithKline Biologicals S.A. | Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
CA2631680A1 (en) * | 2005-12-01 | 2007-06-07 | Conforma Therapeutics Corporation | Compositions containing ansamycin |
TW201008595A (en) | 2005-12-20 | 2010-03-01 | Bristol Myers Squibb Co | Stable protein formulations |
GB0622282D0 (en) | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
GB0918830D0 (en) * | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
JP5754860B2 (en) | 2009-12-03 | 2015-07-29 | ノバルティス アーゲー | Hydrophilic filtration during the manufacture of vaccine adjuvants |
DE102009056883B4 (en) * | 2009-12-03 | 2012-08-16 | Novartis Ag | Vaccine adjuvants and improved methods of making the same |
JP5762437B2 (en) * | 2009-12-10 | 2015-08-12 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Antistatic thermoplastic composition |
JP2015200698A (en) | 2014-04-04 | 2015-11-12 | 日東電工株式会社 | Transparent resin layer, polarizing film with adhesive layer, and image display device |
-
2010
- 2010-06-10 GB GBGB1009676.6A patent/GB201009676D0/en not_active Ceased
-
2011
- 2011-06-08 EP EP11724202.4A patent/EP2579850A1/en not_active Ceased
- 2011-06-08 JP JP2013513676A patent/JP2013528196A/en active Pending
- 2011-06-08 CN CN201180028503.4A patent/CN102917688B/en active Active
- 2011-06-08 BR BR112012031490A patent/BR112012031490A2/en not_active Application Discontinuation
- 2011-06-08 WO PCT/EP2011/059489 patent/WO2011154444A1/en active Application Filing
- 2011-06-08 US US13/702,691 patent/US20130089573A1/en not_active Abandoned
- 2011-06-08 CA CA2801984A patent/CA2801984A1/en not_active Abandoned
-
2015
- 2015-04-06 US US14/679,198 patent/US10406101B2/en active Active
- 2015-10-09 JP JP2015200698A patent/JP6581461B2/en active Active
-
2017
- 2017-09-01 JP JP2017168254A patent/JP6602824B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192222A1 (en) * | 2002-07-23 | 2005-09-01 | Johann Eibl | Pharmaceutical preparations and medicine capable of generating and/or containing thrombin |
US20110162982A1 (en) * | 2009-12-03 | 2011-07-07 | Novartis Vaccines and Diagnostic, GmbH & Co. KG | Methods for producing vaccine adjuvants |
Non-Patent Citations (1)
Title |
---|
Jornitz et al. (Considerations in Sterile Filtration, Part II: The Sterilizing Filter and Its Organism Challenge: A Critique of Regulatory Standards, PDA Journal of Pharmaceutical Science and Technology (March/April 2003) 57(2): 88 - 96) (9 pages) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130084309A1 (en) * | 2010-06-10 | 2013-04-04 | Glaxosmithkline Biologicals S.A. | Process for the preparation of o/w emulsion |
Also Published As
Publication number | Publication date |
---|---|
CA2801984A1 (en) | 2011-12-15 |
CN102917688B (en) | 2016-05-11 |
GB201009676D0 (en) | 2010-07-21 |
US10406101B2 (en) | 2019-09-10 |
JP2016047826A (en) | 2016-04-07 |
WO2011154444A1 (en) | 2011-12-15 |
JP2018030846A (en) | 2018-03-01 |
BR112012031490A2 (en) | 2016-11-01 |
US20150209278A1 (en) | 2015-07-30 |
JP6602824B2 (en) | 2019-11-06 |
EP2579850A1 (en) | 2013-04-17 |
JP2013528196A (en) | 2013-07-08 |
JP6581461B2 (en) | 2019-09-25 |
CN102917688A (en) | 2013-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10406101B2 (en) | Process for the production of a submicron oil in water emulsion | |
CA2801983C (en) | Novel process for the production of an oil in water emulsion | |
DE102009056884B4 (en) | Vaccine Adjuvants and Improved Methods for Making Same | |
KR101643918B1 (en) | Arranging interaction and back pressure chambers for microfluidization | |
KR101523215B1 (en) | Circulation of components during microfluidization and/or homogenization emulsions | |
KR101616735B1 (en) | Hydrophilic filtration during manufacture of vaccine adjuvants | |
DE102009056871A1 (en) | Vaccine adjuvants and improved methods of making the same | |
CN108187040B (en) | Vaccine adjuvant and preparation method thereof | |
DE102009056883B4 (en) | Vaccine adjuvants and improved methods of making the same | |
US20090169659A1 (en) | Purification and endotoxin-removal process | |
US20230218526A1 (en) | Cold filtration of oil-in-water emulsion adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |